Vaccine description | |
---|---|
Target | SARS-CoV-2 |
Vaccine type | Viral vector |
Clinical data | |
Trade names | iNCOVACC |
Routes of administration | Intranasal |
ATC code |
|
Part of a series on the |
COVID-19 pandemic |
---|
![]() |
|
![]() |
iNCOVACC (codenamed BBV154)[1] is an intranasal COVID-19 vaccine candidate developed by Bharat Biotech,[2][3] American company Precision Virologics[4][5] and the Washington University School of Medicine in St Louis, Missouri, United States.[6][7]